Intriguingly, besides the observed modulation of the immune contexture and the induced tumoral PD-L1 upregulation as a potential immune escape mechanism dampening the imatinib-induced anti-tumor response, no direct immunomodulating effects on the tumor cells were identified. Here, CD274 is linked to neoplasm.